Welcome to our dedicated page for YIELD10 BISCIENCE NEW news (Ticker: YTEN), a resource for investors and traders seeking the latest updates and insights on YIELD10 BISCIENCE NEW stock.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) is a pioneering agricultural bioscience company focusing on the development of cutting-edge technologies for significant improvements in crop yield within the United States and Canada. Founded in 1992 and headquartered in Woburn, Massachusetts, Yield10 leverages advanced genetic engineering to develop high-value traits in seeds, targeting the agriculture and food industries through its Trait Factory. The company has a dedicated oilseed development center in Saskatchewan, Canada.
The core mission of Yield10 is to harness the genetic potential of the oilseed Camelina sativa ('Camelina') for the production of sustainable seed products. These products include feedstock oils for renewable diesel and sustainable aviation biofuels, omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical, and aquafeed applications, and future plans for PHA biomaterials to be used as biodegradable bioplastics.
Yield10’s research initiatives are bolstered by strategic partnerships with industry giants such as Bayer AG for soybean traits, Forage Genetics International, LLC for forage sorghum traits, J. R. Simplot Company for potato traits, and GDM Seeds Inc. for evaluating yield traits in soybeans. These collaborations underscore the company’s commitment to innovation and broadening the impact of its technologies.
Significant recent milestones include the development and successful field testing of proprietary winter Camelina varieties engineered for herbicide tolerance. These varieties showed promising results in tolerating glufosinate and Group 2 herbicides, which are crucial for managing weeds and ensuring high yield in crop rotations across North America. This advancement is expected to facilitate the large-scale adoption of Camelina for biofuel and omega-3 oil markets, with the potential for commercial production as early as 2025.
Regulatory progress has been a key aspect of Yield10’s strategy, with USDA-APHIS determining that its genetically engineered Camelina traits are not subject to certain regulations, allowing for expanded planting and breeding in the United States. Additionally, the Canadian Food Inspection Agency has cleared Yield10's E3902 Camelina, which features enhanced oil production and a lighter seed coat.
Yield10 continues to build on its commercial and regulatory achievements, exemplified by the recent agreement with Vision Bioenergy Oilseeds to license Camelina varieties for biofuel feedstock production. This collaboration aims to support the growing demand for low-carbon intensity feedstock oil, aligning with global decarbonization goals.
For more detailed information about Yield10 Bioscience and its innovative endeavors, visit www.yield10bio.com or follow the company on X (formerly Twitter), Facebook, and LinkedIn.
Yield10 Bioscience announced its financial results and corporate update for Q3 2021 will be revealed on November 10, 2021. Management will host a conference call at 4:30 p.m. ET to discuss results and business highlights, followed by a Q&A session. Interested parties can join via phone or live webcast. A replay will be available for those unable to attend the live call. Yield10 is focused on developing Camelina varieties for agricultural innovations and aims to license yield traits to major seed companies.
Yield10 Bioscience, an agricultural bioscience company, announced that its President and CEO, Dr. Oliver Peoples, will speak at the upcoming Maxim Group Global AgTech Conference on October 14, 2021. Dr. Peoples will participate in the "Innovative Food Technologies" panel from 10:30 am to 11:50 am ET. The virtual event features multiple panels and a keynote by Ambassador Kip E. Tom, CEO of Tom Farms. Interested attendees can register via M-Vest. Yield10 focuses on developing superior Camelina varieties for various agricultural applications.
Yield10 Bioscience announces that President and CEO Oliver Peoples, Ph.D. will present at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. The presentation will be available from 7:00 am ET on September 13, with an option for registered investors to engage in one-on-one meetings with management. Yield10 focuses on enhancing agricultural productivity through traits discovered via its 'Trait Factory' platform, specifically targeting improved Camelina varieties for various markets.
Yield10 Bioscience (NASDAQ:YTEN) reported its financial results for Q2 2021, highlighting key advancements in their Camelina platform. The company ended the quarter with $20.6 million in cash, down from $22.7 million. Yield10 faced an operational loss of $3.1 million, compared to $2.1 million in Q2 2020. R&D expenses rose to $1.7 million, while administrative costs increased to $1.6 million, partly due to higher stock-based compensation. The company is focused on scaling up Camelina for food and fuel applications and developing new oil content traits.
Yield10 Bioscience, Inc. (Nasdaq:YTEN) announced it will report its second quarter 2021 financial results on August 11, 2021.
The management will host a conference call at 4:30 p.m. ET to discuss financial results and corporate updates. A replay will be available shortly after the call and accessible until August 25, 2021.
Yield10 focuses on agricultural bioscience, particularly improving Camelina varieties for seed products, aiming to develop superior feedstock oils and PHA bioplastics.
Yield10 Bioscience (Nasdaq: YTEN) has successfully completed the planting of its 2021 Field Test and Seed Scale Up program at various sites across the U.S., Canada, and Argentina. This comprehensive program evaluates elite Camelina varieties and aims to assess seed yield and oil content traits. The company is also scaling up three Camelina varieties for larger plantings in 2022, including a CRISPR-edited trait that could enhance oil content by 4%. Harvest data is expected in Q3 2021, with insights to guide future developments.
Yield10 Bioscience, Inc. (Nasdaq:YTEN) announces two key appointments: Dr. Tichafa Munyikwa as Director of Regulatory Affairs and Dr. Nicholas Renegar as Director of Business Analytics and Operations. Dr. Munyikwa brings 25 years of experience in agriculture and has previously held regulatory roles at major firms. Dr. Renegar, recently earning a Ph.D. from MIT, is expected to enhance Yield10's supply chain analytics. Both appointments aim to strengthen Yield10's efforts in scaling seed production and commercialization of performance traits in Camelina.
Yield10 Bioscience, an agricultural bioscience company, announced that its Chief Science Officer, Dr. Kristi Snell, will present at the 2021 SEED conference on June 16. Her presentation will focus on advancements in plant-based PHB production using Camelina seeds. The research demonstrated that engineered Camelina lines can produce up to 6% PHA of mature seed weight. Dr. Snell emphasized that these findings could link large-scale agricultural production of biodegradable plastics to the global plastics market. Yield10 aims to scale PHA production to meet growing demand in environmentally friendly consumer products.
Yield10 Bioscience, a leader in agricultural bioscience, announced its CEO, Oliver Peoples, will present at the LD Micro Virtual Invitational XI on June 9, 2021, at 3:30 PM ET. The conference runs from June 8-10, 2021, and will focus on the company's innovative seed products and genetic trait discoveries aimed at enhancing agricultural yield. Yield10 aims to commercialize superior varieties of Camelina for oils and bioplastics while targeting major crop companies for licensing. Investors can register for the webcast and schedule meetings with the management team for further insights.
Yield10 Bioscience, Inc. (Nasdaq:YTEN) reported its first-quarter 2021 results, highlighting a cash position of $22.7 million, an increase from $9.7 million at year-end 2020. The company raised $12.7 million through a public offering and generated $3.9 million from warrant exercises. Notably, it reported a net loss of $2.6 million, or $0.60 per share, down from a $3.6 million loss in Q1 2020. Key initiatives include scaling up seed production for new Camelina varieties and advancing omega-3 oil technology for aquaculture, with regulatory compliance progressing. A conference call is scheduled for today at 4:30 p.m. (ET).
FAQ
What is the current stock price of YIELD10 BISCIENCE NEW (YTEN)?
What is the market cap of YIELD10 BISCIENCE NEW (YTEN)?
What does Yield10 Bioscience do?
Where is Yield10 Bioscience headquartered?
What are some recent achievements of Yield10 Bioscience?
Who are Yield10 Bioscience’s key partners?
What is Camelina sativa?
What is the significance of Yield10’s herbicide tolerance tests?
What are Yield10’s future plans for Camelina?
What regulatory milestones has Yield10 achieved?
How is Yield10 addressing the demand for omega-3 oils?
Where can I find more information about Yield10 Bioscience?
